Commercial Aerospace — Collaboration partner share, four years

Products & Services · Collaboration partner share, four years

Raytheon Technologies Commercial Aerospace — Collaboration partner share, four years decreased by 27.6% to $273.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 27.6%, from $377.00M to $273.00M.

Analysis

StatementSegment
CategoryRisk
SignalContext dependent
VolatilityStable
First reportedQ4 2020
Last reportedQ4 2025

How to read this metric

Higher values indicate that a greater share of long-term financial obligations is offloaded to partners, reducing RTX's future capital requirements.

Detailed definition

Represents the portion of commercial aerospace financing commitments and receivables attributable to collaboration partn...

Peer comparison

Similar to long-term project finance risk-sharing metrics in capital-intensive industries.

Metric ID: rtx_segment_commercial_aerospace_collaboration_partner_share_four_years

Historical Data

5 periods
 Q4 '21Q4 '22Q4 '23Q4 '24Q4 '25
Value$423.00M$535.00M$457.00M$377.00M$273.00M
QoQ Change+26.5%-14.6%-17.5%-27.6%
YoY Change+26.5%-14.6%-17.5%-27.6%
Range$273.00M$535.00M
CAGR-35.5%
Avg YoY Growth-8.3%
Median YoY Growth-16.0%
Current Streak3 quarters decline

Frequently Asked Questions

What is Raytheon Technologies's commercial aerospace — collaboration partner share, four years?
Raytheon Technologies (RTX) reported commercial aerospace — collaboration partner share, four years of $273.00M in Q4 2025.
How has Raytheon Technologies's commercial aerospace — collaboration partner share, four years changed year-over-year?
Raytheon Technologies's commercial aerospace — collaboration partner share, four years decreased by 27.6% year-over-year, from $377.00M to $273.00M.
What does commercial aerospace — collaboration partner share, four years mean?
The share of commercial aerospace financial obligations due from partners in four years.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.